BREAX BIOTECH

BreAX Biotech develops a breath-based diagnostic platform leveraging a proprietary single-photon ionization-time-of-flight mass spectrometer. It can provide sensitivity of pptv level (10-12) and a response speed of the second level, realizing high-sensitivity detection and real-time qualitative and quantitative analysis of VOCs in trace to ultra-trace concentrations (10-9~10-12). Breax's human exhaled breath detection mass spectrometer has obtained the NMPA registration certification, becoming the world's first breath detection mass spectrometry platform approved for clinical application. Breax's current clinical focus includes tuberculosis, malignant tumors, infectious diseases, and metabolic diseases.